JANX insider transaction filings
Janux Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen JANX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Campbell David Alan — President and CEO, Director | 2 | — | — | 3 |
Recent Form 4 filings — Janux Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-31 | 4 | Campbell David Alan — President and CEO, Director | Gift (G): 123,840 @ $0 | EDGAR |
| 2026-07-10 | 4 | Campbell David Alan — President and CEO, Director | Option exercise (M): 7,000 @ $4.21 · Option exercise (M): 7,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Simson Jake — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Hernday Natasha — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Kung Winston — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Barrett Ronald W — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | CAPPS VICKIE L — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | DOBMEIER ERIC — Director | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Doyle Janeen Noel — Chief Corp. & Bus. Dev. Ofcr | Sale (S): 4,059 @ $14.03 | EDGAR |
| 2026-05-13 | 4 | Dobek Maria — Vice President, Accounting | Sale (S): 2,038 @ $14.17 | EDGAR |
| 2026-02-04 | 4 | Go William — Chief Medical Officer | Grant/award (A): 44,000 @ $0 · Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Doyle Janeen Noel — Chief Corp. & Bus. Dev. Ofcr | Grant/award (A): 36,000 @ $0 · Grant/award (A): 126,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | McIver Zachariah — Chief Medical Officer | Sale (S): 2,714 @ $13.73 · Grant/award (A): 29,000 @ $0 · Grant/award (A): 101,500 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Dobek Maria — Vice President, Accounting | Sale (S): 1,462 @ $13.73 · Grant/award (A): 18,935 @ $0 · Grant/award (A): 42,600 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | DiRaimondo Thomas — Chief Scientific Officer | Sale (S): 2,505 @ $13.73 · Grant/award (A): 31,400 @ $0 · Grant/award (A): 109,900 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Winter Charles M. — Chief Technical Officer | Sale (S): 2,401 @ $13.73 · Grant/award (A): 28,600 @ $0 · Grant/award (A): 100,100 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Meyer Andrew Hollman — Chief Business Officer | Sale (S): 1,879 @ $13.73 | EDGAR |
| 2026-01-02 | 4 | Campbell David Alan — President and CEO, Director | Sale (S): 8,072 @ $13.73 · Grant/award (A): 96,600 @ $0 · Grant/award (A): 338,100 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,333 @ $10.59 · Sale (S): 2,700 @ $32.85 · Sale (S): 633 @ $33.52 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,333 @ $10.59 · Sale (S): 3,333 @ $30 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 9,999 @ $4.21 · Option exercise (M): 6,666 @ $10.59 · Sale (S): 16,665 @ $30.06 · Option exercise (M): 9,999 (derivative) @ $0 · Option exercise (M): 6,666 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Simson Jake — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hernday Natasha — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Kung Winston — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | McNulty Alana B. — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Gujrathi Sheila — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Barrett Ronald W — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | CAPPS VICKIE L — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | DOBMEIER ERIC — Director | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Doyle Janeen Noel — Chief Corp. & Bus. Dev. Ofcr | Grant/award (A): 44,000 @ $0 · Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,333 @ $4.21 · Sale (S): 2,933 @ $31.95 · Sale (S): 400 @ $32.60 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2025-04-23 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,334 @ $4.21 · Sale (S): 3,334 @ $30 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 304,287 @ $30.56 · Purchase (P): 37,455 @ $31.30 · Purchase (P): 372,093 @ $30.78 · Purchase (P): 110,206 @ $31.02 | EDGAR |
| 2025-03-05 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,334 @ $4.21 · Sale (S): 2,433 @ $31.88 · Sale (S): 901 @ $32.85 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 3,334 @ $4.21 · Sale (S): 2,418 @ $42.08 · Sale (S): 816 @ $42.77 · Sale (S): 100 @ $43.60 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Campbell David Alan — President and CEO, Director | Sale (S): 5,000 @ $60.00 | EDGAR |
| 2025-01-03 | 4 | McIver Zachariah — Chief Medical Officer | Grant/award (A): 26,000 @ $0 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Winter Charles M. — Chief Technical Officer | Grant/award (A): 23,000 @ $0 · Grant/award (A): 80,500 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Campbell David Alan — President and CEO, Director | Grant/award (A): 81,000 @ $0 · Grant/award (A): 283,500 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Robinson Byron — Chief Strategy Officer | Grant/award (A): 28,000 @ $0 · Grant/award (A): 98,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | DiRaimondo Thomas — Chief Scientific Officer | Grant/award (A): 24,000 @ $0 · Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Dobek Maria — Vice President, Accounting | Grant/award (A): 14,000 @ $0 · Grant/award (A): 31,500 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Meyer Andrew Hollman — Chief Business Officer | Grant/award (A): 18,000 @ $0 · Sale (S): 2,922 @ $53.76 · Sale (S): 5,768 @ $54.51 · Sale (S): 3,444 @ $55.76 · Sale (S): 1,000 @ $56.78 · Sale (S): 200 @ $57.37 · +1 more | EDGAR |
| 2024-12-27 | 4 | Campbell David Alan — President and CEO, Director | Sale (S): 25,000 @ $56.19 | EDGAR |
| 2024-12-20 | 4 | Meyer Andrew Hollman — Chief Business Officer | Option exercise (M): 9,880 @ $20.24 · Option exercise (M): 1 @ $14.02 · Option exercise (M): 9,880 (derivative) @ $0 · Option exercise (M): 1 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Campbell David Alan — President and CEO, Director | Sale (S): 15,000 @ $67 | EDGAR |
| 2024-11-27 | 4 | Campbell David Alan — President and CEO, Director | Sale (S): 18,281 @ $51.43 · Sale (S): 6,719 @ $52.04 | EDGAR |
| 2024-11-07 | 4 | CAPPS VICKIE L — Director | Other (J): 2,305 @ $0 | EDGAR |
Recent 8-K events — Janux Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=JANX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →